After several years of intensive preparation — including two years of close cooperation — Dopiopharm GmbH (Germany) and Tikun Olam Europe. (Greece) have decided on a strategic partnership. This cooperation enables almost complete vertical integration, with both companies maintaining their economic independence. As part of the cooperation, mutual exclusivity for cultivation, processing and distribution was agreed.

The partnership focuses on flowers and extracts based on the proven development of the traditional Israeli company Tikun Olam. These products are grown and processed using original plants and using Tikun Olam's standardized methods in a new, state-of-the-art EU-GMP-certified production plant in Greece.

This collaboration gives Dopiopharm the opportunity to introduce cannabis products not yet available in Germany, which have been known for a long time from Tikun Olam's research. Extensive scientific data and studies on these products are also provided. The partnership comprises more than 40,000 patient data, which provide important insights into therapeutic use.

To enter the market, the varieties Erez 20/1 and Midnight 10/14 will first be introduced. Erez was named after the first patient who was treated with cannabis under scientific observation in 2015. Midnight features a unique ratio of THC to CBD, expanding the range of high-quality cannabis products.

Five more varieties are to follow in the next six months, including both highly potent variants and products from Israeli research and from Tikun Olam's modern plants in Los Angeles.

For sales, Dopiopharm relies on Canify AG's established sales platform to ensure an efficient market launch and wide availability of the products.

‍